---
document_datetime: 2025-12-29 12:46:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zyclara.html
document_name: zyclara.html
version: success
processing_time: 0.1270206
conversion_datetime: 2025-12-31 01:36:38.448938
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zyclara

[RSS](/en/individual-human-medicine.xml/66482)

##### Authorised

This medicine is authorised for use in the European Union

imiquimod Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78183)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Zyclara. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zyclara.

For practical information about using Zyclara, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Zyclara and what is it used for?

Zyclara is a cream used to treat actinic keratosis on the face and balding parts of the scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight. Zyclara is used to treat adults whose immune system (the body's natural defences) is working normally when other skin treatments for actinic keratosis cannot be used or are less appropriate. It contains the active substance imiquimod at 3.75% strength (100 mg cream contains 3.75 mg imiquimod).

Zyclara is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substance, but Zyclara is available in a different strength. The reference medicine for Zyclara is Aldara, which contains imiquimod at 5% strength.

## How is Zyclara used?

Zyclara is available as a 3.75% cream in individual sachets. It can only be obtained with a prescription.

One or two sachets of Zyclara are applied in a thin layer to the affected areas of the face or balding scalp once a day before bedtime. The cream should remain on the skin overnight (for about 8 hours) before being washed off. Daily treatment should continue for 2 weeks. This is followed by a 2-week break without treatment and then a further 2 weeks of treatment. For further information, see the package leaflet.

The patient's response to treatment should be evaluated 8 weeks after the end of treatment, and a third 2-week course may be considered if needed. If actinic keratosis does not improve enough with Zyclara, a different treatment should be tried.

If actinic keratosis is cleared after two 2-week courses but then it comes back, it can be treated again with one or two 2-week treatment courses provided these are given after a break of at least 12 weeks from the original treatment.

## How does Zyclara work?

The active substance in Zyclara cream, imiquimod, is an immune response modifier. This means that it uses the immune system to bring about its effect. When imiquimod is applied to the skin, it acts locally on the immune system to trigger the release of cytokines, including interferon. These substances help to kill the abnormal cells in the skin that lead to keratosis.

## What benefits of Zyclara have been shown in studies?

Zyclara has been shown to be effective in clearing actinic keratosis from the skin in two main studies involving 479 patients with actinic keratosis on the face and scalp. Two doses of Zyclara (2.5% and 3.75%) were compared with placebo (a dummy treatment) in these studies, and the main measure of effectiveness was the number of patients whose skin was completely cleared of the actinic keratosis after treatment. Around 36% of patients treated with Zyclara 3.75% cream in the two studies had complete clearance compared with around 6% of patients treated with placebo. Zyclara at a lower strength (2.5%) had a lower clearance rate than the 3.75% strength.

## What are the risks associated with Zyclara?

Most patients using Zyclara experience side effects on the skin where the medicine was applied (most commonly redness, scab formation, dryness and shedding of the skin). About 11% of patients in studies with Zyclara required treatment to be interrupted due to this kind of side effect on the skin. Some other side effects, including headache and tiredness, were also reported. For the full list of side effects and restrictions with Zyclara, see the package leaflet.

## Why is Zyclara approved?

The European Medicines Agency concluded that Zyclara 3.75% cream has been shown to be effective at clearing actinic keratosis from the skin and that its use did not raise significant safety concerns. Treatment with Zyclara has the advantage of being easier to adhere to than Aldara treatment because it has a simpler dosing regimen. In addition, its lower strength allows it to be used across larger areas of the skin and thereby treat more of the affected skin.

The Agency therefore decided that Zyclara's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Zyclara?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zyclara have been included in the summary of product characteristics and the package leaflet.

## Other information about Zyclara

The European Commission granted a marketing authorisation valid throughout the European Union for Zyclara on 23 August 2012.

For more information about treatment with Zyclara, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Zyclara : EPAR - Summary for the public

Reference Number: EMA/470140/2012

English (EN) (77.34 KB - PDF)

**First published:** 13/09/2012

**Last updated:** 24/01/2018

[View](/en/documents/overview/zyclara-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-194)

български (BG) (103.72 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/bg/documents/overview/zyclara-epar-summary-public_bg.pdf)

español (ES) (76.29 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/es/documents/overview/zyclara-epar-summary-public_es.pdf)

čeština (CS) (101.9 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/cs/documents/overview/zyclara-epar-summary-public_cs.pdf)

dansk (DA) (75.33 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/da/documents/overview/zyclara-epar-summary-public_da.pdf)

Deutsch (DE) (77.4 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/de/documents/overview/zyclara-epar-summary-public_de.pdf)

eesti keel (ET) (75.05 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/et/documents/overview/zyclara-epar-summary-public_et.pdf)

ελληνικά (EL) (105.05 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/el/documents/overview/zyclara-epar-summary-public_el.pdf)

français (FR) (77.13 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/fr/documents/overview/zyclara-epar-summary-public_fr.pdf)

hrvatski (HR) (98.09 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/hr/documents/overview/zyclara-epar-summary-public_hr.pdf)

italiano (IT) (76.01 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/it/documents/overview/zyclara-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.57 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/lv/documents/overview/zyclara-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (100.23 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/lt/documents/overview/zyclara-epar-summary-public_lt.pdf)

magyar (HU) (97.24 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/hu/documents/overview/zyclara-epar-summary-public_hu.pdf)

Malti (MT) (103.28 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/mt/documents/overview/zyclara-epar-summary-public_mt.pdf)

Nederlands (NL) (75.63 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/nl/documents/overview/zyclara-epar-summary-public_nl.pdf)

polski (PL) (101.31 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/pl/documents/overview/zyclara-epar-summary-public_pl.pdf)

português (PT) (76.06 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/pt/documents/overview/zyclara-epar-summary-public_pt.pdf)

română (RO) (99.46 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/ro/documents/overview/zyclara-epar-summary-public_ro.pdf)

slovenčina (SK) (100.78 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/sk/documents/overview/zyclara-epar-summary-public_sk.pdf)

slovenščina (SL) (95.54 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/sl/documents/overview/zyclara-epar-summary-public_sl.pdf)

Suomi (FI) (75.6 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/fi/documents/overview/zyclara-epar-summary-public_fi.pdf)

svenska (SV) (76 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

24/01/2018

[View](/sv/documents/overview/zyclara-epar-summary-public_sv.pdf)

## Product information

Zyclara : EPAR - Product Information

English (EN) (733.27 KB - PDF)

**First published:** 13/09/2012

**Last updated:** 22/07/2025

[View](/en/documents/product-information/zyclara-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-885)

български (BG) (423.85 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/bg/documents/product-information/zyclara-epar-product-information_bg.pdf)

español (ES) (346.93 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/es/documents/product-information/zyclara-epar-product-information_es.pdf)

čeština (CS) (344.2 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/cs/documents/product-information/zyclara-epar-product-information_cs.pdf)

dansk (DA) (487.33 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/da/documents/product-information/zyclara-epar-product-information_da.pdf)

Deutsch (DE) (309.07 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/de/documents/product-information/zyclara-epar-product-information_de.pdf)

eesti keel (ET) (190.5 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/et/documents/product-information/zyclara-epar-product-information_et.pdf)

ελληνικά (EL) (363.81 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/el/documents/product-information/zyclara-epar-product-information_el.pdf)

français (FR) (716.84 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/fr/documents/product-information/zyclara-epar-product-information_fr.pdf)

hrvatski (HR) (452.67 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/hr/documents/product-information/zyclara-epar-product-information_hr.pdf)

íslenska (IS) (570.29 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/is/documents/product-information/zyclara-epar-product-information_is.pdf)

italiano (IT) (712.51 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/it/documents/product-information/zyclara-epar-product-information_it.pdf)

latviešu valoda (LV) (245.94 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/lv/documents/product-information/zyclara-epar-product-information_lv.pdf)

lietuvių kalba (LT) (998.94 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/lt/documents/product-information/zyclara-epar-product-information_lt.pdf)

magyar (HU) (372.97 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/hu/documents/product-information/zyclara-epar-product-information_hu.pdf)

Malti (MT) (430.08 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/mt/documents/product-information/zyclara-epar-product-information_mt.pdf)

Nederlands (NL) (442.3 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/nl/documents/product-information/zyclara-epar-product-information_nl.pdf)

norsk (NO) (297.34 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/no/documents/product-information/zyclara-epar-product-information_no.pdf)

polski (PL) (524.9 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/pl/documents/product-information/zyclara-epar-product-information_pl.pdf)

português (PT) (332.79 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/pt/documents/product-information/zyclara-epar-product-information_pt.pdf)

română (RO) (371.09 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/ro/documents/product-information/zyclara-epar-product-information_ro.pdf)

slovenčina (SK) (484.34 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/sk/documents/product-information/zyclara-epar-product-information_sk.pdf)

slovenščina (SL) (468.32 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/sl/documents/product-information/zyclara-epar-product-information_sl.pdf)

Suomi (FI) (714.8 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/fi/documents/product-information/zyclara-epar-product-information_fi.pdf)

svenska (SV) (656.73 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/07/2025

[View](/sv/documents/product-information/zyclara-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000286840 21/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zyclara : EPAR - All Authorised presentations

English (EN) (15.01 KB - PDF)

**First published:** 13/09/2012

**Last updated:** 13/09/2012

[View](/en/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-892)

български (BG) (47.99 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/bg/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_bg.pdf)

español (ES) (15.16 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/es/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_es.pdf)

čeština (CS) (46.66 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/cs/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.32 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/da/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.38 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/de/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (14.99 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/et/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (45.44 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/el/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_el.pdf)

français (FR) (17.41 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/fr/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (73.09 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/hr/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (17.27 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/is/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.9 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/it/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (46.63 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/lv/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (46.4 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/lt/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (44.98 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/hu/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (44.2 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/mt/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.33 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/nl/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.2 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/no/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_no.pdf)

polski (PL) (44.67 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/pl/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.16 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/pt/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_pt.pdf)

română (RO) (42.84 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/ro/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (29.41 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/sk/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.82 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/sl/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.71 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/fi/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (14.96 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

13/09/2012

[View](/sv/documents/all-authorised-presentations/zyclara-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zyclara Active substance imiquimod International non-proprietary name (INN) or common name imiquimod Therapeutic area (MeSH)

- Keratosis
- Keratosis, Actinic

Anatomical therapeutic chemical (ATC) code D06BB10

### Pharmacotherapeutic group

Antibiotics and chemotherapeutics for dermatological use

### Therapeutic indication

Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.

## Authorisation details

EMA product number EMEA/H/C/002387 Marketing authorisation holder

Viatris Healthcare Limited

Damastown Industrial Park Mulhuddart Dublin 15 Dublin Ireland

Opinion adopted 21/06/2012 Marketing authorisation issued 23/08/2012 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zyclara : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.79 KB - PDF)

**First published:** 22/07/2025

[View](/en/documents/procedural-steps-after/zyclara-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zyclara : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (136.45 KB - PDF)

**First published:** 28/11/2013

**Last updated:** 22/07/2025

[View](/en/documents/procedural-steps-after/zyclara-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Zyclara-H-C-PSUSA-00001729-202001 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/652772/2020

English (EN) (130.95 KB - PDF)

**First published:** 18/12/2020

[View](/en/documents/scientific-conclusion/zyclara-h-c-psusa-00001729-202001-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Zyclara : EPAR - Public assessment report

Adopted

Reference Number: EMA/525140/2012

English (EN) (1009.33 KB - PDF)

**First published:** 13/09/2012

**Last updated:** 13/09/2012

[View](/en/documents/assessment-report/zyclara-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zyclara

Adopted

Reference Number: EMA/CHMP/423167/2012

English (EN) (68.76 KB - PDF)

**First published:** 22/06/2012

**Last updated:** 22/06/2012

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zyclara_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Zyclara : EPAR - Product information - tracked changes

English (EN) (318.5 KB - DOC)

**First published:** 22/07/2025

[View](/en/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_en.doc)

[Other languages (24)](#file-language-dropdown-823)

български (BG) (140.56 KB - DOCX)

**First published:**

22/07/2025

[View](/bg/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_bg.docx)

español (ES) (203.24 KB - DOCX)

**First published:**

22/07/2025

[View](/es/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_es.docx)

čeština (CS) (351 KB - DOC)

**First published:**

22/07/2025

[View](/cs/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_cs.doc)

dansk (DA) (144.28 KB - DOCX)

**First published:**

22/07/2025

[View](/da/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (347 KB - DOC)

**First published:**

22/07/2025

[View](/de/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_de.doc)

eesti keel (ET) (297 KB - DOC)

**First published:**

22/07/2025

[View](/et/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_et.doc)

ελληνικά (EL) (423 KB - DOC)

**First published:**

22/07/2025

[View](/el/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_el.doc)

français (FR) (307.5 KB - DOC)

**First published:**

22/07/2025

[View](/fr/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_fr.doc)

hrvatski (HR) (155.78 KB - DOCX)

**First published:**

22/07/2025

[View](/hr/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (146.61 KB - DOCX)

**First published:**

22/07/2025

[View](/is/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_is.docx)

italiano (IT) (316.5 KB - DOC)

**First published:**

22/07/2025

[View](/it/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_it.doc)

latviešu valoda (LV) (381.5 KB - DOC)

**First published:**

22/07/2025

[View](/lv/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_lv.doc)

lietuvių kalba (LT) (359 KB - DOC)

**First published:**

22/07/2025

[View](/lt/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_lt.doc)

magyar (HU) (390.5 KB - DOC)

**First published:**

22/07/2025

[View](/hu/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_hu.doc)

Malti (MT) (148.62 KB - DOCX)

**First published:**

22/07/2025

[View](/mt/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (327 KB - DOC)

**First published:**

22/07/2025

[View](/nl/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_nl.doc)

norsk (NO) (128.51 KB - DOCX)

**First published:**

22/07/2025

[View](/no/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_no.docx)

polski (PL) (407.5 KB - DOC)

**First published:**

22/07/2025

[View](/pl/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_pl.doc)

português (PT) (129.25 KB - DOCX)

**First published:**

22/07/2025

[View](/pt/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_pt.docx)

română (RO) (198.72 KB - DOCX)

**First published:**

22/07/2025

[View](/ro/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (156.37 KB - DOCX)

**First published:**

22/07/2025

[View](/sk/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (369 KB - DOC)

**First published:**

22/07/2025

[View](/sl/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_sl.doc)

Suomi (FI) (334.5 KB - DOC)

**First published:**

22/07/2025

[View](/fi/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_fi.doc)

svenska (SV) (223.06 KB - DOCX)

**First published:**

22/07/2025

[View](/sv/documents/product-information-tracked-changes/zyclara-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 22/07/2025

## Share this page

[Back to top](#main-content)